Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Julphar
Farmers Insurance
Daiichi Sankyo
Medtronic
US Department of Justice
Deloitte
US Army
Citi
McKesson

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 074330

« Back to Dashboard

NDA 074330 describes VERAPAMIL HYDROCHLORIDE, which is a drug marketed by Mylan, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Exela Pharma Scs Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, Watson Labs, and Yaopharma Co Ltd, and is included in fifty-three NDAs. It is available from thirty-six suppliers. Additional details are available on the VERAPAMIL HYDROCHLORIDE profile page.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 074330
Tradename:VERAPAMIL HYDROCHLORIDE
Applicant:Ivax Sub Teva Pharms
Ingredient:verapamil hydrochloride
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 074330
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 074330 ANDA NCS HealthCare of KY, Inc dba Vangard Labs 0615-3588 N 0615-3588-39
VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 074330 ANDA State of Florida DOH Central Pharmacy 53808-0807 E 53808-0807-1

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Jan 31, 1994TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKinsey
Colorcon
Chinese Patent Office
Fuji
Merck
Covington
Daiichi Sankyo
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot